The potential for ischemic preconditioning to reduce infarct size was first recognized more
than 30 years ago [180]. Despite extension of the concept to ischemic postcondition‑ing …

Heart failure (HF) is a leading cause of morbidity and mortality in the United States. Despite
a number of important therapeutic advances for the treatment of symptomatic HF, 1 the …

Rationale: Coronary artery ligation to induce myocardial infarction (MI) in mice is typically
performed by an invasive and time-consuming approach that requires ventilation and chest …

Cardiovascular disease is the leading cause of death in the developed world, and as such
there is a pressing need for treatment options. Cardiac tissue engineering emerged from the …

The increasing prevalence of heart failure poses enormous challenges for health care
systems worldwide. Despite effective medical interventions that target neurohumoral …

The study of heart failure requires viable animal models whereby chronic changes in
myocardial structure and function can evolve and the progression of heart failure and left …

Efficacy of potential treatments for myocardial infarction (MI) is commonly assessed by
histological measurement of infarct size in rodent models. In experiments involving an acute …

Myocardial infarction (MI) is a disease of major consequence in the modern world, causing
permanent, irreversible damage to the heart. Survivors are at risk for developing further …

Female gender and estrogen-replacement therapy in postmenopausal women are
associated with improved heart failure survival, and physiological replacement of 17β …

Matrix metalloproteinase-2 (MMP-2) is prominently overexpressed both after myocardial
infarction (MI) and in heart failure. However, its pathophysiological significance in these …